Improving drug delivery for eye diseases with controllable implants
Undergraduate Research for Dose-Controllable Drug Delivery Implants
This study is testing a new drug implant that uses laser technology to deliver just the right amount of medicine for people with chronic eye conditions like diabetic macular edema and non-infectious posterior uveitis, aiming to reduce side effects and improve treatment results.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10201860 on NIH RePORTER |
What this research studies
This research focuses on enhancing the treatment of chronic eye conditions like diabetic macular edema and non-infectious posterior uveitis by developing a new type of drug implant. The innovative implant allows for precise control of the corticosteroid dosage using laser technology, which aims to minimize side effects commonly associated with current treatments. By addressing the issue of high initial drug concentrations that lead to complications such as glaucoma and cataracts, this approach seeks to improve patient outcomes and extend the effectiveness of the therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic posterior eye diseases such as diabetic macular edema or non-infectious posterior uveitis.
Not a fit: Patients with acute eye conditions or those who do not require corticosteroid treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients suffering from chronic eye diseases.
How similar studies have performed: Previous research has shown that controlled drug delivery systems can improve treatment outcomes, suggesting potential success for this novel approach.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Park, Yoonjee — University of Cincinnati
- Study coordinator: Park, Yoonjee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.